Cargando…

A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint

BACKGROUND: CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaohan, Du, Jun, Liu, Chengdong, Zeng, Hanyi, Chen, Yuting, Liu, Li, Wu, Dehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299557/
https://www.ncbi.nlm.nih.gov/pubmed/34305920
http://dx.doi.org/10.3389/fimmu.2021.688215
_version_ 1783726293057011712
author Zhou, Xiaohan
Du, Jun
Liu, Chengdong
Zeng, Hanyi
Chen, Yuting
Liu, Li
Wu, Dehua
author_facet Zhou, Xiaohan
Du, Jun
Liu, Chengdong
Zeng, Hanyi
Chen, Yuting
Liu, Li
Wu, Dehua
author_sort Zhou, Xiaohan
collection PubMed
description BACKGROUND: CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD161 using The Cancer Genome Atlas (TCGA) Pan-Cancer Data. METHODS: CD161 expression was analysed using RNAseq data from TCGA and the Genotype-Tissue Expression (GTEx) database. HPA, GeneCards, and String database were used to explore the protein information of CD161. The prognostic value of CD161 was analysed using clinical survival data from the TCGA. Enrichment analysis of CD161 was conducted using the R package “clusterProfiler”. We downloaded the immune cell infiltration score of TCGA samples from published articles and online databases and performed a correlation analysis between immune cell infiltration levels and CD161 expression. We further assessed the association between CD161 and immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. FINDINGS: CD161 was differentially expressed and predicted better survival status in most tumour types in TCGA. In addition, CD161 expression was significantly associated with immunoregulatory interactions between lymphoid and non-lymphoid cells. CD161 expression was closely correlated with T cell infiltration, immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. INTERPRETATION: Our results suggest that CD161 is a potential cancer biomarker. CD161 might synergize with other immune checkpoints to regulate the immune microenvironment, which could be applied in the development of new-targeted drugs for immunotherapy. FUNDING: This work was supported by the National Nature Science Foundation of China (grant numbers 81773008, 81672756, 81872399, 81972897), the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province (grant number 2017A030311023), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program: 2017BT01S131 and the Guangzhou Technology Project (grant number 201804010044), National Key R&D Program of China (Grant Nos. 2020YFC2006400), Key-Area Research and Development Program of Guangdong Province (2019B020227004).
format Online
Article
Text
id pubmed-8299557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82995572021-07-24 A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint Zhou, Xiaohan Du, Jun Liu, Chengdong Zeng, Hanyi Chen, Yuting Liu, Li Wu, Dehua Front Immunol Immunology BACKGROUND: CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD161 using The Cancer Genome Atlas (TCGA) Pan-Cancer Data. METHODS: CD161 expression was analysed using RNAseq data from TCGA and the Genotype-Tissue Expression (GTEx) database. HPA, GeneCards, and String database were used to explore the protein information of CD161. The prognostic value of CD161 was analysed using clinical survival data from the TCGA. Enrichment analysis of CD161 was conducted using the R package “clusterProfiler”. We downloaded the immune cell infiltration score of TCGA samples from published articles and online databases and performed a correlation analysis between immune cell infiltration levels and CD161 expression. We further assessed the association between CD161 and immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. FINDINGS: CD161 was differentially expressed and predicted better survival status in most tumour types in TCGA. In addition, CD161 expression was significantly associated with immunoregulatory interactions between lymphoid and non-lymphoid cells. CD161 expression was closely correlated with T cell infiltration, immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. INTERPRETATION: Our results suggest that CD161 is a potential cancer biomarker. CD161 might synergize with other immune checkpoints to regulate the immune microenvironment, which could be applied in the development of new-targeted drugs for immunotherapy. FUNDING: This work was supported by the National Nature Science Foundation of China (grant numbers 81773008, 81672756, 81872399, 81972897), the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province (grant number 2017A030311023), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program: 2017BT01S131 and the Guangzhou Technology Project (grant number 201804010044), National Key R&D Program of China (Grant Nos. 2020YFC2006400), Key-Area Research and Development Program of Guangdong Province (2019B020227004). Frontiers Media S.A. 2021-07-09 /pmc/articles/PMC8299557/ /pubmed/34305920 http://dx.doi.org/10.3389/fimmu.2021.688215 Text en Copyright © 2021 Zhou, Du, Liu, Zeng, Chen, Liu and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, Xiaohan
Du, Jun
Liu, Chengdong
Zeng, Hanyi
Chen, Yuting
Liu, Li
Wu, Dehua
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title_full A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title_fullStr A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title_full_unstemmed A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title_short A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
title_sort pan-cancer analysis of cd161, a potential new immune checkpoint
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299557/
https://www.ncbi.nlm.nih.gov/pubmed/34305920
http://dx.doi.org/10.3389/fimmu.2021.688215
work_keys_str_mv AT zhouxiaohan apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT dujun apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT liuchengdong apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT zenghanyi apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT chenyuting apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT liuli apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT wudehua apancanceranalysisofcd161apotentialnewimmunecheckpoint
AT zhouxiaohan pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT dujun pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT liuchengdong pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT zenghanyi pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT chenyuting pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT liuli pancanceranalysisofcd161apotentialnewimmunecheckpoint
AT wudehua pancanceranalysisofcd161apotentialnewimmunecheckpoint